Increased dose intensity, and a history of cholelithiasis was identified as an independent risk factor for the simultaneous occurrence of HFS and OM, likely due to impaired bile excretion which can lead to PLD accumulation in the body, thereby increasing the risk of developing skin and mucosal toxicity. This evidence concerns the gene GPLD1 and cholelithiasis.